Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell crawled time : 13:20 save search
Nektar Therapeutics Announces It Will Regain Full Rights to Rezpegaldesleukin (REZPEG, NKTR-358), a Novel, First-in-Class Selective Regulatory T-cell (Treg) Therapy in Clinical Development
Published: 2023-04-27 (Crawled : 13:20) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 3.98%
H: 1.86%
C: -0.23%
NKTR | $1.3 -3.7% -3.85% 3.6M
|
Health Technology
|
| O: 0.26%
H: 1.82%
C: -2.21%
nktr-358 t-cell therapeutics therapy
CytomX Therapeutics Announces Milestone Achievement in Probody® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
Published: 2023-01-26 (Crawled : 13:20) - biospace.com/
CTMX | $1.735 -1.42% -1.44% 200K
|
Health Technology
|
| O: 4.58%
H: 6.57%
C: 1.46%
probody collaboration t-cell therapeutics milestone
Nexcella, Inc., a subsidiary of Immix Biopharma, announces poster presentation at the European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell Meeting
Published: 2022-12-28 (Crawled : 13:20) - globenewswire.com
IMMX | News | $2.25 -10.0% -11.11% 190K
|
|
| O: -0.5%
H: 10.05%
C: 9.05%
blood meeting t-cell presentation
Kite to Acquire Tmunity Therapeutics to Pursue Next Generation CAR T-Cell Therapy Advancements in Cancer
Published: 2022-12-20 (Crawled : 13:20) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -3.21%
H: 1.93%
C: 1.35%
acquire t-cell therapeutics therapy cancer
IN8bio Announces FDA Clearance to Initiate a Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma
Published: 2022-12-08 (Crawled : 13:20) - biospace.com/
INAB | $1.04 4.0% 3.85% 130K
|
|
| O: 0.81%
H: 2.01%
C: -6.02%
inb-400 fda clearance trial phase 2 glioblastoma
Lyell Immunopharma Presents New Data at SITC Highlighting its Growing Pipeline of T – Cell Reprogramming Technologies and Product Candidates Targeting Solid Tumors
Published: 2022-11-07 (Crawled : 13:20) - globenewswire.com
LYEL | $2.34 -1.68% -1.71% 910K
|
Professional, Scientific, and T...
|
| O: 5.02%
H: 0.0%
C: -8.47%
growing tumors
Atossa Therapeutics, Inc. to Acquire Stake in Privately Held Dynamic Cell Therapies as Part of Overall CAR-T Strategy
Published: 2022-11-01 (Crawled : 13:20) - globenewswire.com
ATOS | $1.41 4.44% 4.26% 2.3M
|
Health Technology
|
| O: -0.13%
H: 3.67%
C: -5.93%
acquire car-t
Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy to Treat B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Published: 2022-10-06 (Crawled : 13:20) - biospace.com/
MBIO | $0.3819 -0.55% -1.05% 200K
|
Health Technology
|
| O: 1.96%
H: 1.88%
C: -3.85%
FBIO | $1.81 2.26% 2.21% 440K
|
Health Technology
|
| O: 1.33%
H: 6.7%
C: -1.03%
mb-106 leukemia trial therapy
CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130™ for the Treatment of Cutaneous T-Cell Lymphomas (CTCL)
Published: 2022-09-28 (Crawled : 13:20) - biospace.com/
CRSP M | $56.14 1.04% 1.03% 1.7M
|
Health Technology
|
| O: 0.83%
H: 5.1%
C: 4.33%
ctx130 treatment fda designation crispr lymphomas t-cell granted therapeutics therapy rmat
Viracta Therapeutics Announces Orphan Drug Designation Granted by the European Commission for Nana-val for the Treatment of Peripheral T-cell Lymphoma
Published: 2022-09-07 (Crawled : 13:20) - biospace.com/
VIRX | $0.8971 -4.18% -4.36% 79K
|
Manufacturing
|
| O: 1.16%
H: 12.64%
C: 10.57%
treatment designation drug t-cell granted therapeutics
Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform
Published: 2022-07-20 (Crawled : 13:20) - globenewswire.com
PRTG | $0.299 35.17% 26.02% 140K
|
Mining, Quarrying, and Oil and ...
|
| O: -1.23%
H: 19.49%
C: 7.45%
biotech platform
AlloVir Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients
Published: 2022-06-07 (Crawled : 13:20) - biospace.com/
ALVR | $0.74 -2.23% -2.28% 530K
|
Health Technology
|
| O: -1.55%
H: 7.85%
C: 4.71%
treatment ongoing kidney
ImmunityBio Announces First Participants Have Been Enrolled in Lung-MAP Trial Studying Anktiva to Activate NK and T Cells in Non-Small Cell Lung Cancer
Published: 2022-04-25 (Crawled : 13:20) - biospace.com/
IBRX | $4.92 -6.11% -6.5% 3.5M
|
Manufacturing
|
| O: -3.12%
H: 2.86%
C: 0.0%
trial cancer enroll
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.